Jacqueline Cloos, PhD, of Amsterdam UMC, Amsterdam, The Netherlands, shares her views on the future treatment and management of acute myeloid leukemia (AML), and explains multiple potentially viable methods that need further research. Prof. Cloos talks on the prospects of personalized care becoming an increasingly accessible option due to the various subtypes of AML, highlighting how measurable residual disease (MRD), once standardized and regulated with the help of the AML Working Group, may help to achieve that. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.